

Cover Story
Clinical
Proven curative regimens containing platinum-based drugs—cisplatin and carboplatin—have become largely unavailable because of a nationwide drug shortage. The institutions that have some supplies of cisplatin and carboplatin are setting up algorithms for rationing their dwindling stocks, which usually means giving top priority to patients treated with curative intent and denying standard-of-care treatment to patients who cannot be cured but who can still benefit from these drugs.
In Brief


Clinical Roundup


Drugs & Targets
Trending Stories
- Montefiore Einstein Director Edward Chu dies of glioblastoma at 66
- Arnold D. Kaluzny, longtime adviser to the NCI and health services researcher, dies at 87
- Natalie Phelps, whose clinical trial was delayed due to RIFs, dies of colon cancer
- Oncofertility coverage mandates expand to 21 states and DC as political momentum builds
Gaps persist as patients face harrowing decisions and huge copays - Duke Officials Silenced Med Student Who Reported Trouble in Anil Potti’s Lab
- GLP-1 drugs linked to dramatically lower death rates in colon cancer patients
















